CAS: 70260-16-1; (2-Bromothiophen-3-yl)Methanol

上下游产品

CAS号71637-34-8 3-噻吩甲醇 | CAS号40032-76-6 2-溴-3-(溴甲基)噻吩 | CAS号189331-42-8 3-acetoxymethyl... | CAS号1860-99-7 2-溴噻吩-3-甲醛

📜3-甲基噻吩置于n-溴代丁二酰亚胺(Nbs),水,Calcium Carbonate,过氧化苯甲酰体系中,用 1,4-二氧六环,四氯化碳,氯仿,溶剂黄146 作为反应溶剂,化学反应 16.08H,反应生成 (2-溴-3-噻吩)甲醇
参考文献:调节nlo发色团的共轭位置以降低偶极矩并增强有机材料的电光活性的研究
标题:调节nlo发色团的共轭位置以降低偶极矩并增强有机材料的电光活性的研究
摘要:为了提高发色团的一阶超极化性(β)并将其转化为高宏观电光活性,在噻吩π-上引入了一系列具有不同推挽电子基团的新型二阶非线性光学发色团.设计并合成了用于调节生色团的形状和偶极矩(μ)的共轭桥.这些生色团基于相同的噻吩π共轭桥,其中供体(n,N-二乙基苯胺)和受体(2-(3-Cyano-4,5,5-Trimethylfuran-2(5 H(-亚烷基)丙二腈或丙二腈)分别连接到噻吩的位置2和3,从而获得了飞旋镖状而不是棒状的形状.此外,作为辅助受体或供体的贫电子基团br(溴原子)或富电子基团dea(n,N-二乙基苯胺)连接到噻吩的5位.另外,根据dsc和tga分析的结果,所有生色团均显示出非常好的热稳定性.通过紫外可见分析和dft计算,可以得出结论,带有额外的富电子基团作为辅助供体的发色团表现出更好的分子间电荷转移(ict)吸收和更低的homo-Lumo能隙(δe).此外,具有相同推挽结构的回旋镖
DOI:10.1039/c9Tc05704H

专利信息

专利号:US-6852711-B2
优先权日:1998-09-11
标题:HIV protease inhibitors
发明人：BOYER JR FREDERICK EARL; DOMAGALA JOHN MICHAEL; ELLSWORTH EDMUND LEE; GAJDA CHRISTOPHER ANDREW; HAGEN SUSAN ELIZABETH; LOVDAHL MICHAEL JAMES; LUNNEY ELIZABETH ANN; MARKOSKI LARRY JAMES; PRASAD JOSYULA VENKATA NAGENDR; TAIT BRADLEY DEAN
权利人:AGOURON PHARMA
摘要:The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

专利号:US-9351954-B2
优先权日:2009-12-04
标 题:Multicyclic compounds and methods of use thereof
发明人：SHAO LIMING; CAMPBELL JOHN EMMERSON; HEWITT MICHAEL CHARLES; CAMPBELL UNA; HANANIA TALEEN G
权利人:SUNOVION PHARMACEUTICALS INC; PGI DRUG DISCOVERY LLC
摘要:Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. For example, disclosed herein are compounds having formula (IIa) shown below, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the variables are defined herein. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.